A few of our partners
Interested in joining us to bring next-generation precision oncology care to the patients you serve?
Expanded treatment selection across therapy classes
Combined DNA and quantitative RNA profiling from limited tumor tissue provides the opportunity for treatment with a broader range of therapeutic modalities.
Strata Select™ is a pan-solid tumor molecular profiling test for patients with advanced cancer that provides treatment selection guidance for immunotherapy and beyond.
Validate next-generation biomarkers
The partnership of your institution with Strata creates a continuous learning loop to advance new biomarkers that improve outcomes.
Better biomarkers can expand benefit, increase response rates and reduce treatment costs.
Collaborate on innovative clinical research
Strata PATH is a multi-arm platform trial testing novel treatment hypotheses for existing FDA-approved therapies across multiple tumor types.
A range of therapeutic classes will be evaluated in Strata PATH including targeted therapies, antibody-drug conjugates, immunotherapies and angiogenesis inhibitors.
Deliver value-based, patient-centered care
Leverage the novel biomarkers Strata is developing to succeed in risk-based agreements.
Improve quality while lowering costs.
Customized service and support
Strata Oncology provides the infrastructure and expertise to deliver precision cancer care to large populations.